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Abstract
Giardia lamblia is a causative agent of persistent diarrhoea widespread in regions with low
hygienic standards. Laboratory research is based on cloned lines issuing from various patient
isolates typed in the late 1980s and 90s using restriction analysis and serology. In the present
study, we compared the well-characterized strain WBC6 with another clone of the parent WB
isolate termed WBA1 and with a clone from another isolate, GS/M-83-H7, using shotgun
mass spectrometry proteomics. We identified 398 proteins differentially expressed between
the GS and both WB isolates and 97 proteins differentially expressed between the two WB
isolates. We investigated the expression levels of the predominant variant-specific surface pro-
teins (VSPs) in each clone and matched the previously described major VSPs of each strain to
the corresponding open reading frame sequences identified by whole-genome sequencing
efforts. Furthermore, since the original WB isolate comes from a patient treated with metro-
nidazole, we compared the susceptibilities of the strains to nitro compounds, as well the
expression levels of enzymes involved in nitro reduction and on the corresponding enzyme
activities and found distinct differences between the three strains.
Introduction
The diplomonadid Giardia lamblia (syn. G. duodenalis, G. intestinalis), an early diverging,
anaerobic eukaryote (Adam, 2001; Cernikova et al., 2018), is a causative agent of persistent
diarrhoea widespread in regions with low hygienic standards (Hemphill et al., 2019). After
stomach passage, cysts ingested via contaminated food or water or via direct personal contact
transform into trophozoites which colonize the duodenum and cause the symptoms peaking
around 1 week post infection. In general, hosts in good physical condition recover within 2–3
weeks. In rare cases, the infection persists and becomes chronical causing severe damage of the
intestinal epithelium (Allain et al., 2017) occasionally resulting in the development of irritable
bowel syndrome (Litleskare et al., 2018). Eight different genotypes or assemblages, labelled
A to H, have been identified, assemblages A and B having the broadest spectrum identifying
animals as well as humans (Heyworth, 2016). Furthermore, assemblage E isolates may cause
human giardiasis, as well (Zahedi et al., 2017). Thus, giardiasis occurs in humans as well as in
other mammals and can be regarded as a zoonosis (Thompson, 2004). Human giardiasis is
treated with the nitroimidazole metronidazole as first-line and the benzimidazole albendazole
as second-line drug. Quinacrine, one of the first antigiardial drugs, is not in use, anymore
(Gardner and Hill, 2001; Nash, 2001).
The largest part of laboratory research is based on the strain WBC6, an assemblage A1
strain obtained by limited dilution cloning from the WB isolate obtained from duodenal con-
tents from a patient suffering from chronical giardiasis refractory to either quinacrine or
metronidazole (MET) treatments (Smith et al., 1982b). The isolate originates from
Afghanistan (Smith et al., 1982a) and was axenized at the NIH (Nash et al., 1985). The
WBC6 strain, cloned by F. Gillin via limited dilution in 1983 (Campbell and Faubert,
1994), eagerly produces cysts in vitro (Campbell and Faubert, 1994), is amenable to genetic
manipulation (Furfine and Wang, 1990; Sun et al., 1998), and its growth in vitro is less affected
by the culture medium composition than other strains (own observations, see ‘Materials and
methods’ section). Consequently, WBC6 is extensively used to investigate intracellular pro-
cesses associated with en- and excystation of the parasite (Faso and Hehl, 2011; Zamponi
et al., 2017) and has been the first Giardia strain where the complete genome has been
sequenced (Morrison et al., 2007). Unfortunately, in many articles before this hallmark, the
strain is referred to as WB only. This is insofar confusing, as other clones from the same ori-
ginal isolate with distinct characteristics exist. The most striking of these characteristics is
related to a unique feature of G. lamblia, namely antigenic variation (Nash, 2002; Adam
et al., 2010). The genome of WBC6 and of other strains that have been sequenced so far
(see www.giardiadb.org) contain several hundred open reading frames (ORFs) encoding the
so-called variant-specific surface proteins (VSPs). According to a recently published
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chromosome-scale reference genome, the genes encoding for
VSPs, as well as other highly repetitive genes, are distributed
over all five chromosomes (Xu et al., 2020). VSPs have the follow-
ing properties in common: a signal peptide targeting the protein
to the surface, a highly variable N-terminus with frequent
CXXC-motifs (where X may be any amino acid), a nearly invari-
ant C-terminus of 38 amino acids containing a CRGKA motif, a
hydrophobic domain forming the membrane anchor (Adam
et al., 2010). The N-terminus of VSPs is highly immunogenic.
VSPs therefore constitute the main surface antigens of G. lamblia
trophozoites. According to a generally admitted hypothesis, one
single trophozoite expresses only one VSP at the same time
(Nash et al., 1990b, 2001). During encystation, however, several
VSPs may be expressed by the same cell (Carranza et al., 2002).
The switching from one VSP to another, thus antigenic variation,
at least indirectly depends in all likelihood, on posttranscriptional
mechanisms (Kulakova et al., 2006; Prucca et al., 2008, 2011;
Prucca and Lujan, 2009).
Studies in the 80s and 90s based on monoclonal antibodies
raised against specific epitopes revealed the presence of major
VSPs in a given WB trophozoite population. A well-characterized
member of these major surface antigens is VSPA6 (in the litera-
ture also referred to as CRP170 due to approximate size of 170
kDa) that is expressed by several subclones of the WB isolate
(Adam et al., 1988). VSPA6 is recognized by the cytotoxic mono-
clonal antibody (mAb) 6E7. Trophozoites resistant to mAb 6E7
express a different pattern of VSPs (Nash et al., 1988). Even in
the absence of this selective pressure, other VSPs recognized by
different monoclonal antibodies appear after many generations
(Nash et al., 1990a).
According to further studies, mAb 6E7 recognizes an octapep-
tide motif (GAAPLYKK) present in 65 amino acid repeats distrib-
uted in different numbers over the VSP primary sequence
(Mowatt et al., 1994) suggesting an evolution by gene duplication
(Yang and Adam, 1995).
Conversely, trophozoites of WBC6 express a predominant
VSP, named TSA417, exhibiting a peptide molecular mass of
72.5 kDa as predicted by the corresponding gene sequence
(Gillin et al., 1990). Complement-dependent killing of tropho-
zoites during exposure to anti-recombinant TSA417 antiserum
provides a selective advantage for minor populations of
non-TSA417-expressing trophozoites already present in the ori-
ginal culture (Meng et al., 1993). Furthermore, WBC6 tropho-
zoites bearing non-TSA417-type VSPs appear during the
process of excystation (Meng et al., 1993; Svärd et al., 1998).
Another extensively studied G. lamblia strain, namely clone
GS/M-83-H7, representing an assemblage B genotype, originates
from the human isolate GS obtained in Alaska and axenized by
isolation of trophozoites from infected neonatal mice (Nash
et al., 1985). This clone expresses a major surface antigen, VSP
H7, which is immuno-reactive to a specific, cytotoxic mAb
(mAb G10/4). VSP H7 has an apparent molecular mass of ca.
57 kDa (Nash and Mowatt, 1992). For GS/M-83-H7, in vitro anti-
genic variation replacing VSP H7 by diverse other VSPs on the
surface of trophozoites occurs at about one variation event per
6.5 generations in comparison to one variation event per 12–13
generations in the original WB isolate (Nash et al., 1990a).
Since GS/M-83-H7 infects humans as well as mice, immune
responses to VSP H7 have been investigated not only in vitro
(Müller et al., 1996) but also in mouse models (Gottstein et al.,
1990; Müller and Gottstein, 1998). These studies show that anti-
genic variation occurs in vivo as a reaction to humoral immune
responses in both hosts (Nash et al., 1990c; Bienz et al., 2001;
Müller and von Allmen, 2005).
Recent shotgun mass spectrometry proteome studies have
revealed that WBC6 trophozoite populations and trophozoite
populations from other assemblage A strains express an impres-
sive number of VSPs at the same time (Emery et al., 2014,
2015). Other studies have revealed that strain-dependent antigenic
diversification of trophozoites occurs upon selective drug pressure
(Emery et al., 2018; Emery-Corbin et al., 2018; Müller et al.,
2019).
Using this sensitive method, we compared the well-
characterized strain WBC6 with another clone of the parent
WB isolate in the following termed WBA1. This clone grows
only in a culture medium with strictly defined components and
is refractory to antigenic variation, as previously shown (Nash
et al., 1990a), and according to our own observations.
Moreover, this strain is refractory to encystation (Campbell and
Faubert, 1994). We included the strain GS/M-83-H7 as an out-
group into our comparison expecting that more proteins are dif-
ferentially expressed between this clone and either WB clone than
between both WB clones. We were particularly interested in the
expression levels of the predominant VSPs in each clone and
matched the previously described major VSPs of each strain to
the corresponding ORF sequences identified by whole-genome
sequencing efforts. Furthermore, since the original WB isolate
comes from a patient treated with the nitroimidazole metronida-
zole, and since antigenic variation has been shown to be influ-
enced by drug exposure (Müller et al., 2019), we compared the
susceptibilities of the strains to nitro compounds and had a closer
look on enzymes involved in nitro reduction and on the corre-
sponding enzyme activities.
Materials and methods
Chemicals
If not otherwise stated, all biochemical reagents were from Sigma
(St Louis, MO, USA). Nitazoxanide (NTZ) was synthesized at the
Department of Chemistry and Biochemistry, University of Bern,
Switzerland (Ch. Leumann). NTZ, albendazole (ALB) and MET
were kept as 100 mM stock solutions in DMSO at −20°C.
Axenic culture, harvest and storage of G. lamblia trophozoites
Trophozoites from G. lamblia WBC6 (C6), WBA1 (A1) and GS/
M-83-H7 (H7) were grown under anaerobic conditions in 10 mL
culture tubes (Nunc, Roskilde, Denmark) on modified TYI-S-33
medium as previously described (Clark and Diamond, 2002). In
order to ensure the growth of the A1 and H7 clones, the compo-
nents were as close as possible to the isolation medium, in par-
ticular heat-inactivated adult bovine serum (Biofluids, Rockville,
MD, USA) and casein peptone (Becton Dickinson, Cockeysville,
MD, USA). Prior to shotgun mass spectrometry analysis, the cul-
tures were routinely passaged two times. Subcultures were per-
formed by inoculating 100 μL of cells from a confluent culture
detached by cooling (see below) to a new tube containing 10
mL culture medium (Müller et al., 2006). Trophozoites were har-
vested by incubation on ice for 15 min followed by centrifugation
(300 × g, 10 min, 4°C). Pellets were washed three times with ice-
cold PBS, counted and stored at −80°C for subsequent proteomic
analysis or for enzymatic assays.
Proteomics
Cell pellets were lysed in 100 μL 8 M urea/100 mM Tris/HCl pH 8/
cOmpleteTM protease inhibitor cocktail (Roche Diagnostics,
Rotkreuz, Switzerland) by incubation for 15 min at room tem-
perature followed by 15 min in an ultrasonic water bath.
Proteins were reduced and alkylated with 10 mM DTT for 30
min at 37°C and 50 mM iodoacetamide for 30 min at 37°C.
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Proteins were precipitated at −20°C by addition of 5 volumes cold
acetone and incubation at −20°C overnight. All liquid was care-
fully removed and the pellet dried in ambient air for 15 min
before reconstitution of proteins in 200 μL of 8 M urea, 50 mM
Tris-HCl pH 8.0. Protein concentration was determined by
Bradford assay and an aliquot corresponding to 10 μg protein
was digested by trypsin (1:50 trypsin/protein ratio) for 6 h at
37°C after dilution of urea concentration to 1.6 M with 20 mM
Tris-HCl pH 8.0 and 2mM CaCl2. The digests were acidified
with TFA (1%) and analysed by LC-MS/MS. Three repetitive
injections of an aliquot corresponding to 500 ng protein digest
was separated on an EASY-nLC 1000 coupled to a QExactive
mass spectrometer (ThermoFisher Scientific). Peptides were
trapped on an Acclaim PepMap100 C18 pre-column (3 μM, 100
Å, 75 μM × 2 cm, ThermoFisher Scientific, Reinach, Switzerland)
and separated by backflush on a C18 column (3 μM, 100 Å, 75
μM × 15 cm, Nikkyo Technos, Tokyo, Japan) by applying a 60
min gradient of 5% acetonitrile to 40% in water, 0.1% formic
acid, at a flow rate of 400 nLmin−1. Peptides of m/z 360–1400
were detected with a resolution of 70 000 applying an automatic
gain control (AGC) target of 1E06 and a maximum ion injection
time of 50 ms. A top 10 data-dependent method for precursor ion
fragmentation with a stepped 27% normalized collision energy
was applied with the following settings: precursor isolation
width of 2 m/z, resolution 17 500, AGC of 1E05 with a minimum
target of 1E03, maximum ion time of 110 ms, charge exclusion of
unassigned and 1+ ions, peptide match on and dynamic exclusion
for 20 s, respectively.
The MS data were obtained from three biological replicates, with
three technical replicates for each biological replicate, for each strain.
All MS data were processed by MaxQuant (version 1.5.4.1) with
matching between runs for the same strain activated, but not between
different strains, in order to avoid over-interpretationof the data.The
sample sets were interpreted separately by MaxQuant. Fragment
spectra were interpreted against a recent Giardia protein sequence
database including both WB and GS datasets in fasta format
(GiardiaDB-5.0_GintestinalisAssemblageA_AnnotatedProteins;
GiardiaDB-5.0_GintestinalisAssemblageB_AnnotatedProteins_v2).
The trypsin cleavage rule allowed amide bond cleavage after lysine
and arginine but not if a proline follows and up to threemissed cleav-
age sites, fixed carbamidomethylationmodificationof cysteines, vari-
able oxidation of methionine and acetylation of protein N-termini.
Precursor and fragment mass tolerances were set to 10 and 20
ppm, respectively. Peptide spectrum matches, peptide and protein
group identifications were filtered to a 1% false discovery rate
(FDR) based on reversed database sequence matches, and a min-
imum of two razor or unique peptides were required to accept a pro-
tein group identification. Protein identifications considered as
contaminations (e.g. trypsin or BSA) as well as proteins identified
only by site (considered by MaxQuant developers as very likely
false positives) were removed for statistical validation. The normal-
ized label-free quantification (LFQ) protein group intensities as cal-
culated by MaxQuant were used for relative proteome
quantifications. First, we imputed missing protein LFQ values for
samples in any condition group when there were at least two LFQ
intensities in one group (downshift of 2.5 S.D. with a width of 0.3
S.D.). When comparing VSPs only, peptides unique to a single VSP
protein were used for the calculation of protein intensities based on
the sum of the three most intense peptides (Top3 approach).
Before summing, missing peptide intensities were imputed sample
group wise, when there were at least two valid intensities (downshift
of 1.8 S.D. with a width of 0.3 S.D.). The resulting protein intensities
were named iTop3. This process left proteins without values in one
or the other group. For Welch’s t-tests, those missing protein inten-
sitieswere replaced by imputed values from the very lowend of inten-
sity distributions in analogy to the LFQ imputation (downshift 2.5
S.D., width of 0.3 S.D.). An FDR-controlled Benjamini–Hochberg pro-
cedure was used for the correction of P values. A log2-fold change of
at least one and a corrected P value of 0.05 were required to be con-
sidered as significant. Statistical testing and imputation were made
with a home-made R script run under R-Studio. Our main goal
was to identify the VSPs in the H7 proteome. To do this, we had to
use the assemblage B database. Since most of the other proteins
share high homologies with those from assemblage A strains and
are found in both databases, they are called orthologues. We elimi-
nated those proteins that were expressed in both strains sharing the
same ORF numbers (e.g. GL50803_10167 in assemblage A and
GSB_10167 in assemblage B) via the GenesbyOrthologues tool on
theGiardiaDB site (www.giardiabd.org). Small differences in peptide
sequences or SNPs were not considered. They can easily be identified
by comparing the sequences of orthologues provided by GiardiaDB.
For comparative quantification of orthologues, the LFQ values corre-
sponding to GL50803 were used for assemblage A strains and the
values corresponding to GSB were used for assemblage B strains.
The mass spectrometry proteomics data have been deposited
to the ProteomeXchange Consortium via the PRIDE
(Perez-Riverol et al., 2019) partner repository with the dataset
identifier PXD017597.
Drug susceptibility assays
Drug susceptibility of G. lamblia trophozoites of the strains C6,
A1 and H7 was tested in 96-well plates inoculated with 103 tro-
phozoites per well and MET, NTZ or ALB at various concentra-
tions (dilution factor 2) and incubated in an anaerobic growth
chamber (85% N2, 10% H2, 5% CO2). After 72 h (C6, A1) or
96 h (H7), growth of cells was monitored by a vitality assay
based on the reduction of resazurin (Alamar Blue) to a pink prod-
uct that was assayed fluorimetrically (Bénéré et al., 2007). The
IC50 values were determined using the logit-log algorithm as
described (Müller and Hemphill, 2013).
To determine minimal inhibitory concentrations (MIC), WT
and C4 trophozoites were inoculated in the presence of increasing
amounts (dilution series by a factor 2) of the nitro compounds
MET, NTZ or ALB as a control. The tubes were incubated at
37°C for 96 h (C6, A1) or 120 h (H7). The MIC was determined
by observing the wells under the microscope starting from higher
to lower concentrations. The concentration at which the first living
trophozoites were visible is given as the MIC (Müller et al., 2018).
Enzyme assays
Trophozoite crude extracts were prepared by suspending tropho-
zoite pellets in 50 mM Tris-Cl−, pH 7.0, containing 0.05%
triton-X-100 and a protease inhibitor mix (Halt, ThermoFisher
Scientific, Waltham, MA) according to the manufacturer’s
instructions. NAD(P)H oxidase and quinone reductase activities
were measured in 96-well microtiter plates containing 100 μL of
a reaction mix containing buffer (50 mM Tris-Cl−, pH 7.0), 0.5
mM thiazolyl blue tetrazolium (MTT), 0.5 mM NADH or
NADPH and 5 μL of crude extract. To measure quinone reductase
activity, 0.1 mM menadione was added to the mix. The plates were
incubated at 37°C under aerobic conditions. Substrate and
enzyme blanks were included. After different time points, the
reaction was stopped by adding 100 μL of pure ethanol thus solu-
bilizing the product formed by the reduction of MTT, formazan
(Prochaska and Santamaria, 1988; Müller et al., 2015).
Nitroreductase activity was quantified via the reduction of
7-nitrocoumarin (7-NC) to 7-aminocoumarin (7-AC) using the
reaction mix as described above, without MTT and 0.1 mM
7-NC, with the same volumes and under the same conditions
of incubation. Enzyme and substrate blanks were included. The
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reaction was stopped by adding 100 μL of 50 mM HCl lowering the
pH to allow full protonation of the reaction product (Wagner,
2009). 7-AC was quantified by fluorimetry with excitation at
365 nm and emission at 455 nm (Müller et al., 2015).
Absorption at 590 nm (MTT-based assays) and fluorescence
intensities were quantified using a 96-well multimode plate reader
(Enspire; Perkin-Elmer, Waltham, MA, USA). Protein contents of
crude extracts were determined by the Bradford method
(Bradford, 1976) using a commercial kit (Biorad, Hercules, CA,
USA).
Results and discussion
Mass spectrometry analysis of proteins expressed in G. lamblia
trophozoites
Shotgun mass spectrometry of the proteomes of trophozoites of
the strains WBC6 (C6), WBA1 (A1) and GS/M-83-H7 (H7)
allowed the identification of 24 739 unique peptides matching
to 2 368 proteins (Table S1). Overall analysis of the data by prin-
cipal component analysis (PCA) revealed that biological and tech-
nical replicates clustered together for each strain. The proteomes
of the three strains formed non-overlapping clusters. A1 and C6
were separated by PC2 only, whereas the proteome of H7 was
separated by both other strains PC1 and PC2 (Fig. 1). A PCA
with strains A1 and C6 only is shown in Fig. S1.
Differentially expressed proteins
To get a better estimation of ‘true’ differentials between assem-
blage and B strains, orthologues present in both A and B strains
have been subtracted using the GenesbyOrthologues function
implemented in the GiardiaDB. Without eliminating these ortho-
logues from the comparison, WBC6 vs H7 would yield 1320 dif-
ferentials, WBA1 vs H7 would yield 1264 differentials. This
analysis revealed that between strains C6 and A1, 97 proteins
were differentially expressed, as compared to 454 proteins
between strains C6 and H7 (Fig. 2). Comparison of differentially
expressed proteins between the strains H7 vs the strains C6 and
A1 revealed that 253 proteins had higher levels in both WB strains
than in H7, and 146 proteins had higher levels in H7 than in the
WB strains. Besides hypothetical proteins, the categories with the
highest numbers of differentials comprised proteins involved in
cytoskeleton, adhesion and organelle transport, intermediary
metabolism, gene expression and development, and signalling
(Table 1). Strain H7 expressed a unique set of 13 VSPs different
from the VSP sets expressed in both WB strains. H7 and the
WB clones belong to different assemblages, it is not surprising
that an order of magnitude more differential proteins are identified
between H7 and the WB clones than between the two WB clones.
Some of the proteins overexpressed in H7, in particular proteins
involved in signalling or attachment, may contribute to the broad
Fig. 1. Principal component analysis of proteome dataset from G. lamblia tropho-
zoites of different strains. Trophozoites of the strains WBC6 (C6), WBA1 (A1) and
GS/M-83-H7 (H7) were compared by MS shotgun analysis as described in ‘Materials
and methods’ section. For each strain, all technical and biological (square, circle, dia-
mond) replicates are shown.
Fig. 2. Venn diagram detailing the number of differentially expressed proteins in G.
lamblia trophozoites of different strains. Trophozoites of the strains WBC6 (C6),
WBA1 (A1) and GS/M-83-H7 (H7) were subjected to MS shotgun analysis as described
in ‘Materials and methods’ section. Orthologues present in both A and B strains have
been subtracted using the GenesbyOrthologues function implemented in the
GiardiaDB.
Table 1. Number of differentially expressed proteins in strain GS/M-83-H7 as
compared to both WBC6 and WBA1 trophozoites
(Hypothetical) function
Higher levels in
WBC6 and WBA1
Higher levels in
GS/M-83-H7
Variant-specific surface
proteins
4 13
Cytoskeleton, adhesion and
organelle transport
34 15
Intermediary metabolism 54 22
Signalling 16 13
Gene expression, cell cycle,
development
48 17
Chaperones 10 0
Transport of metabolites 9 5
Hypothetical 82 60
Total 253 145
The strains were grown and processed for MS shotgun analysis as described in ‘Materials
and methods’ section. The proteins are grouped with respect to their hypothetical
functions.
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Table 2. Overview of ORFs differentially expressed in WBC6 (C6) as compared to WBA1 (A1) trophozoites
(Hypothetical) function Protein ORF number in Giardia database
Higher expression in C6
Variant-specific surface proteins VSP-88 101 074
VSP-169 112 801
VSP-44 113 450
VSP-5 113 797
VSP-149 116 477
VSP-38 13 194
VSP-160 137 612
VSP-188 137 613
VSP-77 137 617
VSP-8 137 618
VSP-3 137 740
VSP-186 14 586
VSP-100 33 279
VSP-49 41 472
VSP-121 5812
Cytoskeleton, adhesion and organelle
transport
Protein 21.1 101 168
Ankyrin repeat protein 14 745
IFT complex B 17 223
Protein 21.1 (Ankyrin repeat) 17 608
ENC6 protein 24 372
Trichohyalin 32 375
Protein 21.1 3760
Cyst wall protein 2 5435
Synaptic glycoprotein SC2 88 581
Dynein heavy chain 94 440
Intermediary metabolism Ubiquitin carboxyl-terminal hydrolase 14 102 710
Peroxiredoxin 1 14 521
2,5-diketo-D-gluconic acid reductase 151 884
NAD(P)H:menadione oxidoreductase 17 150
Nitroreductase Fd-NR2 22 677
L-serine dehydratase 24 662
Glucosamine-6-phosphate deaminase 8245
Adenylate kinase 90 402
Signalling Kinase, AGC PKA 11 214
Kinase, NEK 13 215
Kinase, NEK 137 733
Kinase, CAMK CAMKL 14 661
ARF GAP 17 561
AMP-activated protein kinase, gamma-1 subunit 3414
Gene expression, cell cycle, development Chromosome segregation protein SMC 10 027
Threonyl and alanyl tRNA synthetase second additional domain 150 018
CDC19 17 413
Golgi/cell cycle associated protein, putative 17 472
Preimplantation protein 3 3417
(Continued )
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host spectrum of this strain, which infects humans as well as
animals, as reviewed elsewhere (Müller and von Allmen, 2005).
When comparing the set of the 97 differentially expressed pro-
teins between C6 and A1 in more detail, it turned out that –
besides 32 hypothetical proteins – 22 VSPs differed between
these strains. Eleven differential proteins were involved in signal-
ling, 11 cytoskeleton-related proteins, 10 involved in intermediary
metabolism, 10 proteins with functions in gene expression and
development, and one with a chaperone-like function (Table 2).
Thirty-four proteins were also significantly lower in strain H7
as compared to C6 (Fig. 2), in particular the 15 C6-specific
VSPs (see ‘Antigenic variation’ section) and 19 proteins with vari-
ous functions, as highlighted in Table 2.
Antigenic variation
The strains investigated in this study had been characterized with
respect to their (major) surface antigens. Therefore, in a first step,
we matched the original antigens by protein–protein blasts to
sequences found in the GiardiaDB. It turned out that sequences
attributed to TSA417 (strain C6) matched to GL50803_113797,
annotated as VSP5 and to GL50803_113450, annotated as
VSP44. Concerning strain H7, the sequence published for
VSPH7 matched to GSB150963.
Surprisingly, the sequence of CRP170, the predominant surface
antigen of strain A1, matched to a sequence annotated as a hypo-
thetical protein, namely GL50803_221693 with 100% identity
and a total score of 3491 (Fig. S2). The GL50803_221693 ORF
encodes a 228 kDa protein containing 2259 amino acids. The iden-
tified peptides of GL50803_221693 covered unique protein
sequences near the N terminus (aa 75–151), followed by 26 repeats
of the peptide TNPSDPTGTCVSAVDCQGSAGYYTDDS-VSD
AKECKKCNAPCTACAGTADKCTKCDANGAAPYLKK (thus
containing the GAAPYLKK motif recognized by mAb6E7), and
a unique sequence near the C-terminus (aa 1812–2223). Regions
where trypsin produces too long/hydrophobic or too short pep-
tides, namely the two transmembrane helices at the C- and
N-terminal part of the protein, were missed as can be expected
by the used technology (Fig. S3). Proteins encoded by other
ORFs sharing high score homologies with CRP170, namely
GL50803_137752 and GL50803_37093 (Fig. S2), were not detected
in the present dataset.
In a second step, we compared the LFQ intensities of the
major VSPs in all strains (Fig. 3). In the case of strain C6,
TSA417 (VSP5; ORF113797) was still one of the dominating
VSPs, followed by VSP-8 (ORF 137618), VSP-188 (ORF
137613) and four other VSPs in the range of 107 LFQ units
(Fig. 3A). Amongst these VSPs were the gene products of ORFs
101074 and 137618. ORF 101074 (VSP88) was identical to the
Table 2. (Continued.)
(Hypothetical) function Protein ORF number in Giardia database
SBDS C-terminal domain protein, putative 40 521
Pelo protein 5892
Chaperones T-complex protein 1, β subunit 11 397
Hypothetical (25 proteins)
(12 proteins also in H7)
Higher expression in A1
Variant-specific surface proteins High cysteine membrane protein VSP-like 112 135
High cysteine membrane protein Group 1 11 309
VSP-175 137 608
High cysteine membrane protein Group 1 16 318
CXC-rich protein 17 476
VSP A6 (annotated as hypothetical protein) 221 693
High cysteine membrane protein Group 6 41 942
Cytoskeleton, adhesion and organelle
transport
Dynein heavy chain 17 243
Intermediary metabolism Glycosaminoglycan polysaccharide lyase 10 238
Nitroreductase family protein 15 307
Signalling Kinase, NEK 14 216
Kinase, CAMK CAMKL 17 566
Serine/threonine protein phosphatase 5 21 498
Protein kinase NEK family protein 152 721
Gene expression, cell cycle, development MCM2 15 344
DNA replication licensing factor MCM6 17 390
RNA binding protein, putative 92 031
Hypothetical (8 proteins)
The strains were grown and processed for MS shotgun analysis as described in ‘Materials and methods’ section. For each strain, three biological replicates have been tested (with three
technical replicates per biological replicate). The proteins in this list had significantly different expression levels both in iLFQ and iTop3 values. The proteins with different expression levels
also in strain GS/M-83-H7 are printed in italics.
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sequence of AAG16629, annotated as VSP9B10A (Nash et al.,
2001). ORF 137618 (VSP8) covered AF293416, annotated as
VSPB10B (Carranza et al., 2002) only to 88% leaving 70 amino
acid gaps. In a previously published comparative proteomics
study (Emery et al., 2015), a strain WB expressed four of the
major VSPs identified in WBC6, namely VSP38 (ORF 13194),
VSP49 (ORF 41472), VSP149 (ORF 116477) and the previously
mentioned VSP188.
In strain A1, GL50803_221693 (homologous to VSPA6) was –
by far – the most predominant VSP with LFQ values above 1011,
but not the only one identified. The five next abundant VSPs had,
however, expression levels three or more magnitudes lower than
VSPA6. Interestingly, VSPA6 was expressed in strain C6 as well,
but only at LFQ levels below 107 (Fig. 3B). In strain H7, 13
VSPs with LFQ levels around 107 or higher were identified.
VSPH7 (GSB150963) was not predominant, five other VSPs hav-
ing equal or higher expression levels (Fig. 3C).
Moreover, we have reinvestigated the most predominant VSPs
of the three strains using only peptides labelled as being unique to
a single VSP by using iTop3 protein intensities (see ‘Materials and
methods’ section and Table S2). The corresponding values are
shown as Supplementary Fig. S4. Some minor VSPs disappeared,
but the overall pattern of the strains did not change as compared
to the analysis based on LFQ values.
These results show that A1 had the most ‘homogeneous’ popu-
lation of trophozoites with respect to their surface proteome. The
two other strains yielded mixed trophozoite populations with five
or more equally dominant subpopulations.
The fact that VSPA6 was expressed at low levels in strain C6
prompted us to investigate whether this VSP was found in the
proteome of the same strain grown on a different medium. The
corresponding dataset had been published earlier in a different
context (Müller et al., 2019). Since the corresponding ORF
(221693) was annotated as a hypothetical protein and not as a
Fig. 3. Quantitative assessments of the major variant-specific surface proteins (VSPs).
Trophozoites of the strains WBC6 (C6), WBA1 (A1) and GS/M-83-H7 (H7) were sub-
jected to MS shotgun analysis as described in ‘Materials and methods’ section. For
all VSPs, mean values ± one standard deviation for LFQ intensities (×106) in three bio-
logical replicates are shown. The VSPs are termed by their respective accession num-
bers in the GiardiaDB (GL50803 for C6 and A1; GSB for H7). A, VSP pattern of strain
C6; B, VSP pattern of strain A1; C, VSP pattern of strain H7.
Fig. 4. Determination of drug susceptibilities. The strains WBC6 (C6), WBA1 (A1) and
GS/M-83-H7 (H7) were exposed to serial dilutions of the nitro compounds metronida-
zole (MET) and nitazoxanide (NTZ), as well as of albendazole (ALB). IC50 values were
determined as described in ‘Materials and methods’ section and are given in μM (MET,
NTZ) or nm (ALB). Diamonds correspond to the IC50s, bars to the 95% confidence
intervals.
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VSP, the corresponding expression levels had been overlooked. As
shown in Table S3, VSPA6 became the third most abundant VSP
in C6 trophozoites grown on a new culture medium differing
from the old one merely with respect to the quality of the
serum and the peptone. Moreover, VSPA6 had very high expres-
sion levels in two Australian assemblage A1 isolates investigated
in the same study (Müller et al., 2019). Thus, VSPA6 cannot be
regarded as a unique marker for WBA1 and related clones.
Susceptibility to antigiardial drugs and reductase activities
Since the strains C6 and A1 had been isolated from a patient trea-
ted with MET, we were curious to investigate whether these strains
differed in their susceptibilities to nitro drugs from the strain H7
isolated from a different source. Interestingly, strain A1 had
higher IC50s than strain C6 when exposed to MET and to NTZ,
but not to ALB. Strain H7 was more susceptible to MET and to
ALB than both strains C6 and A1 (Fig. 4). The MIC of both
nitro drugs were even nearly one order of magnitude higher on
A1 than on both other strains (Table 3). When comparing
IC50s and MICs from different strains, one should consider that
these constants measure different things, as reviewed elsewhere
(Müller and Hemphill, 2013). In the case of bacteria exposed to
antibiotics, elevated MICs are regarded as indicative for ‘resist-
ance’, whereas elevated IC50s without elevated MICs indicate ‘tol-
erance’ (Brauner et al., 2016). In our case, strain A1 would be at
the edge of ‘resistance’ with, however, much lower MICs than
those of resistant strains generated in the laboratory (Müller
et al., 2018).
To see whether these differences matched to differences in
reductase activities, we assayed NAD(P)H oxidase activity, quin-
one reductase activity and nitroreductase activity in crude extracts
from the three strains (Fig. 5). Crude extracts from strains A1 and
H7 had significantly lower NADPH oxidase, but not lower
NADH oxidase activities than strain C6 (Fig. 5A). Quinone reduc-
tase activity with menadione as a substrate was at equal levels in
crude extracts from all three strains (Fig. 5B). Nitroreductase
activity, assayed as the full reduction of 7-NC to 7-AC was
slightly, but significantly increased in A1 as compared to C6
crude extracts. Crude extracts from strain H7 had an intermediate
activity (Fig. 5C).
Enzymes involved in nitro reduction or detoxification processes
These findings prompted us to have a closer look at the expression
levels of enzymes involved in nitro reduction and related detoxi-
fication processes. The values are listed in Table 4. Strain C6 had
significantly higher levels of the nitroreductase NR1 than the two
other strains. Conversely, A1 was the only strain expressing the
homologous NR family protein without ferredoxin domain at
its N-terminus. C6 and A1, but not H7, expressed a 2Fe-2S ferre-
doxin, the only free ferredoxin detected in the proteome of the
strains investigated in this study. Moreover, the ferredoxin-
domain protein hydrogenase 1 was identified in all strains with
significantly higher levels in strain H7.
C6 had significantly higher levels of A-type flavoprotein and of
NAD(P)H oxidase than the two other strains. All other proteins
investigated within this context, in particular both
pyruvate-ferredoxin-oxidoreductases, did not differ between the
strains (Table 4).
Conclusions
Our results, in particular those concerning the surface proteome
of the investigated strains, show that care must be taken when
referring to these strains using the VSP terminology established
three decades ago as a result of their reactivity with monoclonal
Table 3. Determination of minimal inhibitory concentrations (MICs)
Compound C6 A1 H7
MET 6.25 50 6.25
NTZ 1.25 10 1.25
ALB 0.125 0.125 0.125
The strains WBC6 (C6), WBA1 (A1) and GS/M-83-H7 (H7) were exposed to serial dilutions of
the nitro compounds metronidazole (MET) and nitazoxanide (NTZ), as well as of
albendazole (ALB). MICs were determined as described in ‘Materials and methods’ section
and are given in μM.
Fig. 5. Reductase activities in crude extracts of G. lamblia trophozoites. The assays
were performed as described in ‘Materials and methods’ section using either
NADH (white bars) or NADPH (black bars) as cofactors. A, NAD(P)H oxidase; B, quin-
one reductase with menadione as a substrate; C, nitroreductase with 7-nitrocoumarin
as a substrate. Mean values ± one standard deviation for three independent assays
are given. Values superscribed by different letters are significantly different (two-
sided t-tests; P < 0.05).
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antibodies. A given antibody may cross-react with epitopes on
VSPs encoded by a different ORF with high sequence identity
and/or with VSPs carrying epitopes with a similar secondary
structure, as illustrated by the following example. Using the
monoclonal antibody Mab9B10, for instance, two different
VSPs, namely VSP9B10A (Nash et al., 2001) and VSP9B10B
(Carranza et al., 2002) were identified, which correspond to two
major VSPs (VSP88 for sure and VSP8 most likely) of strain
WBC6 as shown in our dataset.
Consequently, the hypothesis that one single trophozoite
expresses one single VSP could be modified in the sense that
one single trophozoite may express VSPs that may be encoded
by one or more ORFs. This hypothesis could be verified only
by single-cell proteomics (Dou et al., 2019; Liu et al., 2020), a
method which has not been established for G. lamblia, so far.
Rich in potential trypsin and chymotrypsin cleavage sites
inside a highly repetitive motif (covering three-quarters of its pri-
mary sequence in the case of VSPA6), the digest by pancreas pro-
teases (or by proteases released by decaying trophozoites) may
yield free epitopes blocking otherwise cytotoxic antibodies. Such
a scenario may be relevant for the outcome of G. lamblia infec-
tions because cytotoxic anti-VSP antibodies turned out to possess
a modulatory function on the proliferative parasite population
characteristics in the experimental murine host as reviewed else-
where (Müller and Gottstein, 1998; Müller and von Allmen,
2005). Moreover, VSPs may have enzymatic functions as evi-
denced in the case of VSP9B10A (ORF 101074; VSP88), which
has cysteine protease activity (Cabrera-Licona et al., 2017).
Other functions such as enzyme activities or interactions with
receptors on other trophozoites or on host cells remain to be
elucidated.
Since the WB isolate issues from a patient treated with MET,
the clones A1 and C6 may represent two different strategies to
deal with this drug pressure. WBC6 retains a higher flexibility
with respect to gene expression and is able to generate a highly
nitro drug-resistant offspring in a few selection cycles (Müller
et al., 2007) differing from the original clone with respect to
appropriate physiological adaptations and an adapted proteome
(Müller et al., 2018; Müller et al., 2019). Conversely, WBA1
may represent a ‘freezed’ status with a moderate nitro drug resist-
ance at the price of a loss in gene expression flexibility.
This hypothesis including the identification of elements con-
trolling this flexibility, e.g. in the differential signalome of both
strains as evidenced in our dataset, would require further
investigations.
Supplementary material. The supplementary material for this article can
be found at https://doi.org/10.1017/S0031182020000657.
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